$2.11
+0.11 (+5.50%)
Open$2.04
Previous Close$2.00
Day High$2.15
Day Low$2.04
52W High$2.81
52W Low$1.31
Volume—
Avg Volume597.7K
Market Cap152.00M
P/E Ratio—
EPS$-1.39
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+685.3% upside
Current
$2.11
$2.11
Target
$16.57
$16.57
$14.06
$16.57 avg
$23.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.33M | 18.18M | 17.68M |
| Net Income | -947,103 | -802,247 | -886,084 |
| Profit Margin | -4.9% | -4.4% | -5.0% |
| EBITDA | -1,287,077 | -1,124,832 | -1,061,399 |
| Free Cash Flow | -739,760 | -479,993 | -441,081 |
| Rev Growth | +21.0% | +13.7% | -3.4% |
| Debt/Equity | 0.36 | 0.44 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |